SE0104340D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0104340D0
SE0104340D0 SE0104340A SE0104340A SE0104340D0 SE 0104340 D0 SE0104340 D0 SE 0104340D0 SE 0104340 A SE0104340 A SE 0104340A SE 0104340 A SE0104340 A SE 0104340A SE 0104340 D0 SE0104340 D0 SE 0104340D0
Authority
SE
Sweden
Prior art keywords
sup
new compounds
active compounds
new
compounds
Prior art date
Application number
SE0104340A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Ratan Bhat
James Empfield
Sven Hellberg
Mike Klimas
James Woods
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104340A priority Critical patent/SE0104340D0/xx
Publication of SE0104340D0 publication Critical patent/SE0104340D0/xx
Priority to AU2002359164A priority patent/AU2002359164A1/en
Priority to JP2003554090A priority patent/JP4465188B2/ja
Priority to EP02793678A priority patent/EP1458707B1/fr
Priority to US10/499,217 priority patent/US7205314B2/en
Priority to AT02793678T priority patent/ATE361287T1/de
Priority to ES02793678T priority patent/ES2284964T3/es
Priority to DE60219954T priority patent/DE60219954T2/de
Priority to PCT/SE2002/002373 priority patent/WO2003053330A2/fr
Priority to JP2009201189A priority patent/JP2009280618A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
SE0104340A 2001-12-20 2001-12-20 New compounds SE0104340D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0104340A SE0104340D0 (sv) 2001-12-20 2001-12-20 New compounds
AU2002359164A AU2002359164A1 (en) 2001-12-20 2002-12-18 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
JP2003554090A JP4465188B2 (ja) 2001-12-20 2002-12-18 新規な化合物
EP02793678A EP1458707B1 (fr) 2001-12-20 2002-12-18 Nouveaux dérivés de l' Indol-2-one
US10/499,217 US7205314B2 (en) 2001-12-20 2002-12-18 Compounds for the treatment of dementia related diseases
AT02793678T ATE361287T1 (de) 2001-12-20 2002-12-18 Neue indol-2-on derivate
ES02793678T ES2284964T3 (es) 2001-12-20 2002-12-18 Nuevos derivados de indol-2-ona.
DE60219954T DE60219954T2 (de) 2001-12-20 2002-12-18 Neue Indol-2-on Derivate
PCT/SE2002/002373 WO2003053330A2 (fr) 2001-12-20 2002-12-18 Nouveaux composés
JP2009201189A JP2009280618A (ja) 2001-12-20 2009-09-01 新規な化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104340A SE0104340D0 (sv) 2001-12-20 2001-12-20 New compounds

Publications (1)

Publication Number Publication Date
SE0104340D0 true SE0104340D0 (sv) 2001-12-20

Family

ID=20286439

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104340A SE0104340D0 (sv) 2001-12-20 2001-12-20 New compounds

Country Status (9)

Country Link
US (1) US7205314B2 (fr)
EP (1) EP1458707B1 (fr)
JP (2) JP4465188B2 (fr)
AT (1) ATE361287T1 (fr)
AU (1) AU2002359164A1 (fr)
DE (1) DE60219954T2 (fr)
ES (1) ES2284964T3 (fr)
SE (1) SE0104340D0 (fr)
WO (1) WO2003053330A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60221283T2 (de) 2001-12-21 2008-03-20 Astrazeneca Ab Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
WO2006044687A2 (fr) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Inhibiteurs de kinase
MX2008000017A (es) 2005-06-28 2008-03-26 Sanofi Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
MX2008000956A (es) 2005-07-26 2008-03-27 Sanofi Aventis Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa.
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
US8642598B2 (en) 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
PT2102164E (pt) 2006-12-27 2011-01-21 Sanofi Aventis Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina
BRPI0720862A2 (pt) 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
MY155009A (en) 2006-12-27 2015-08-28 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
PT2125744E (pt) 2006-12-27 2011-07-01 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
JP5405316B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノリン誘導体
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
JP5713893B2 (ja) 2008-06-24 2015-05-07 サノフイ Ｒｈｏ−キナーゼ阻害剤としての置換イソキノリン類及びイソキノリノン類
CN102131785B (zh) 2008-06-24 2014-10-29 赛诺菲-安万特 6-取代的异喹啉和异喹啉酮
EP2303845B1 (fr) 2008-06-24 2013-09-18 Sanofi Isoquinoléine substituée bi- et polycyclique et dérivés d'isoquinoléine utilisées comme inhibiteurs de la rho-kinase
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CA2810954A1 (fr) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Composes heterocycliques et leur utilisation en tant qu'inhibiteurs de la glycogene synthase kinase-3
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2023097151A1 (fr) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Procédés de traitement d'agitation et d'autres symptômes comportementaux associés à la démence

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US6576656B1 (en) 1998-08-20 2003-06-10 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivative
EP1136493A1 (fr) 2000-03-23 2001-09-26 Sanofi-Synthelabo Dérivés de 2-(thienopyridinyl)pyrimidones, 2-(furopyridinyl)pyrimidones, 2-(isoquinolinyl)pyrimidones, 2-(pyridoindolyl)pyrimidones et 2-(benzofuropyridinyl)pyrimidones

Also Published As

Publication number Publication date
AU2002359164A1 (en) 2003-07-09
ES2284964T3 (es) 2007-11-16
EP1458707B1 (fr) 2007-05-02
DE60219954T2 (de) 2008-01-17
JP4465188B2 (ja) 2010-05-19
DE60219954D1 (de) 2007-06-14
US7205314B2 (en) 2007-04-17
JP2009280618A (ja) 2009-12-03
EP1458707A2 (fr) 2004-09-22
JP2005513082A (ja) 2005-05-12
ATE361287T1 (de) 2007-05-15
WO2003053330A2 (fr) 2003-07-03
WO2003053330A3 (fr) 2003-10-30
US20050065170A1 (en) 2005-03-24
AU2002359164A8 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
SE0104340D0 (sv) New compounds
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
SE0102439D0 (sv) New compounds
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
SE0102438D0 (sv) New compounds
SE9902987D0 (sv) Novel compounds
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
UY27592A1 (es) Nuevo uso
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
SE0104334D0 (sv) Therapeutic agents
TW200745111A (en) New compounds
SE0104341D0 (sv) New use
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
SE0100569D0 (sv) New compounds
SE0104331D0 (sv) Novel compounds
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
SE9902765D0 (sv) Novel compounds
MY133527A (en) Isoquinoline derivatives